Hookipa Pharma reports Q2 EPS ($1.52), consensus ($1.25)

Reports Q2 revenue $1.29M, consensus $7.09M. The revenue decrease was primarily due to lower partial recognition of the upfront and milestone payments under the Roche collaboration as a result of the termination of the collaboration agreement with Roche. Hookipa’s cash, cash equivalents and restricted cash as of June 30, was $77.4M compared to $117.5M as of December 31, 2023. The decrease was primarily attributable to cash used in operating activities. “It is an honor to be appointed CEO of Hookipa at such an important time for the company. I am optimistic about the company’s prospects, based on the strength of the pipeline, early clinical data, and the experience and dedication of the accomplished team we have in place,” said Malte Peters, CEO. “Our best-in-class Phase 2 data that were presented at ASCO has generated significant momentum among investigators and this has enhanced the pace of enrollment in our ongoing Phase 2 study. In the meantime, preparations are well underway for our AVALON-1 pivotal adaptive Phase 2/3 trial of eseba-vec, expected to be initiated in the fourth quarter of this year.”